{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Spruce Biosciences, Inc."},"Symbol":{"label":"Symbol","value":"SPRB"},"Address":{"label":"Address","value":"2001 JUNIPERO SERRA BOULEVARD,SUITE 640 SUITE 740, DALY CITY, California, 94014, United States"},"Phone":{"label":"Phone","value":"+1 415 655-4168"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH)."},"CompanyUrl":{"label":"Company Url","value":"https://www.sprucebiosciences.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Javier Szwarcberg","title":"Chief Executive Officer & Director"},{"name":"P. J. Ramtin","title":"Senior Vice President-Business Operations"},{"name":"Ralph William Charlton","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}